Hims Adds Lilly's Zepbound and Foundayo to Its Platform

What did Lilly and Hims & Hers agree to?

Announced on November 6, 2026, the agreement allows eligible patients prescribed Lilly medications by licensed Hims & Hers providers to access Zepbound and Foundayo without leaving the telehealth platform, at the same self-pay prices offered through LillyDirect.

Orbitrum Investor Impact

Why could the agreement matter to Hims & Hers?

It removes an additional purchasing step that previously sent patients to LillyDirect and gives Hims access to Lilly's branded obesity treatments alongside Novo Nordisk's existing offering, potentially reducing customer abandonment and supporting its transition away from mass-compounded weight-loss medications. Neither company disclosed a Hims-specific revenue share or expected sales contribution.

Does the 40%–45% Zepbound self-pay figure represent Hims sales?

No. Lilly told Reuters that 40% to 45% of Zepbound sales overall come through self-pay channels, not specifically through Hims; monthly starting prices under the agreement are $299 for Zepbound and $149 for Foundayo, matching LillyDirect.

How did the agreement affect Hims stock?

Reuters reported that Hims shares rose more than 7% in premarket trading on November 6 following the announcement, reflecting a positive initial market reaction, although the agreement provides no quantified revenue or margin guidance.

What should investors watch next?

The key indicators are integration and rollout timing, customer adoption, prescription conversion and fulfillment performance; Hims identified these factors, along with pricing and maintaining the agreement, as execution risks, while committing to preserve independent clinical prescribing decisions.